Pricing
Start for free.Upgrade when you'reready for more
Flexible plans for every investor.
Whether you're just getting started or looking to level up your strategy, Zacks Insight offers flexible plans to match your needs.
Basic
For everyday research
10 prompts/month
Conversational research AI
Robust screening across fundamentals, technicals, ownership, analyst data
Premium
For portfolios needing deeper analysis
Everything in Pro
Unlimited research prompts
Advanced Portfolio Analysis
Second opinion Report
Built for investors, by investors.Get plain-English, data-backed answers, powerful screens, and portfolio analysis with professional-grade rationale.
Compare PlansChoose your Zacks Insight plan according to your needs. |
Free/ Lifetime
|
$12.99/ month
|
$89.49/ month
|
|---|---|---|---|
| Higher usage limits | |||
| Conversational AI (ask in plain English) | |||
| Robust screening (250+ fields per ticker) | |||
| AI-driven in-chat data panels | |||
| Zacks Rank (short-term buy/hold/sell) | |||
| Zacks Recommendations (long-term buy/hold/sell) | |||
| Analyst equity report & research summaries | |||
| Fundamentals (estimates, P/E, margins, D/E, etc.) | |||
| Technicals (52-wk range, volume, short interest, etc.) | |||
| Analyst consensus & price targets | |||
| Insider & institutional ownership | |||
| Sector & industry data | |||
| Analyst upgrades/downgrades | |||
| Earnings calendar (upcoming reports) | |||
| Personalize portfolio analysis (upload holdings) | |||
| Intake questionnaire & risk profile | |||
| Personalized second-opinion analysis (buy/sell & re-weights) | |||
| Personalized portfolio report (PDF) | |||
| Analysis of current sector concentrations | |||
| Right-Fit Asset Mix — Current vs Recommended | |||
| Market-Cap Tilt — Concentrations vs Optimal | |||
| Sector Posture — Over/Underweights & Adjustments | |||
| Style Balance — Growth/Value & Quality Alignment | |||
| Benchmarks & performance diagnostics (Alpha, VaR, Tracking Error, valuation vs SPY) |
The next chapter is almost here
Join the waitlist for early access to portfolio diagnosis, the optimized second opinion, and human guidance when it counts.